In the News April 2013 JDRF is the only global organization with a strategic plan to deliver a continuous flow of life-changing therapies and, ultimately, a cure for T1D.  Past JDRF investments have yielded significant advances and taught us that progress towards our goals will be made incrementally over time. ...

This way to read more

On August 10, the drug Lucentis, licensed by Genentech, was approved by the U.S. Food and Drug  Administration (FDA) for the treatment of diabetic macular edema (DME).  Studies of Lucentis (ranibizumab injection)—funded by JDRF and the National Institutes of Health’s (NIH) Special  Diabetes Program (SDP)—demonstrated the drug’s safety and effectiveness...

This way to read more

On August 3, JDRF, in collaboration with The Leona  M. and Harry  B. Helmsley Charitable Trust,  announced the award of a $4.6  million grant to the laboratory of Camillo Ricordi, M.D., of the Diabetes Research  Institute at the University of Miami. The three-year grant will  fund  research in the area...

This way to read more

JDRF-funded scientists provided new evidence that a two-drug combination can extend the function of pancreatic islet transplants that have begun to fail and restore insulin  independence in some transplant recipients with type 1 diabetes (T1D). This research finding was presented at the American Diabetes Association’s 72nd Scientific Sessions in Philadelphia...

This way to read more

The JDRF-supported Joslin  50-Year Medalist Study has shown that more than  40 percent of people who  have had type 1 diabetes (T1D) for at least 50 years have no or mild  diabetic retinopathy, or eye disease, suggesting that many  of the Medalists are somehow protected from this common complication of...

This way to read more

Two  JDRF-funded pilot trials  in human subjects represent significant advances in the development of a safe and effective artificial pancreas system for the treatment of type 1 diabetes (T1D). One study demonstrated, for the first time,  the feasibility of a wearable artificial pancreas in a “real-world” setting. The second study...

This way to read more

Advancing  Type 1 Diabetes  Science Every  day, JDRF leverages the expertise and innovation of distinguished researchers from across the globe to support better treatments, prevention, and ultimately a cure for type 1 diabetes (T1D). In this issue of Top Research  Highlights, please read about news from the American Diabetes Association’s...

This way to read more

The search  for a stable liquid formulation of glucagon has occupied many  diabetes researchers for years. While currently the biosynthetic hormone is manufactured in dry  form to ensure  stability and shelf life, the delivery of glucagon in conjunction with insulin  in standard diabetes pumps—a long-sought development— would require a viable...

This way to read more

TrialNet is an international network of researchers exploring ways to prevent and delay the progression of T1D. A blood test is offered that identifies an increased risk for T1D up to 10 years before symptoms appear. www.DiabetesTrialNet.org Read more »

Top Research Highlights can be found by clicking this link. Read more »

Artificial pancreas approved for US outpatient testing Read more »

The Spring issue of Cool Research News can be found by clicking this link. Read more »

Learn more about different projects being funded at JDRF Research. Interested in Clinical Trials? www.diabetestrialnet.org. JDRF Works to Speed Delivery of Faster Acting Insulin: www.countdown.jdrf.org. Read more »